Andy Hahn (@OncHahn) ranks #18 among US gu cancer KOLs on X in 2026, by engagement from fellow physicians. 30 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: JNJ-6143. CMS Open Payments lists $21,875 in 2025 general payments.
At a Glance
- 1 posts naming a trial in 2026
- 1 trials discussed by name
- GU Cancer: US #18 · 30 physicians engaged
- Leading physician voice: #1 of 16 physicians on JNJ-6143
- CMS Open Payments lists $21,875 in 2025 general payments.
This Month
What Andy Hahn has posted in the last 30 days. Updated November 10, 2026.
Thrilled to share updated results from JNJ-6143, the AR-BRD4 RIPTAC therapy, presented by @BGarmezy. Totally novel MOA was well tolerated, oral pill and produced significant benefit for pts (PSA90 50%, ORR 68%). P2 trial active now and more coming. Lots of potential! https://t.co/spwrXBg5ZZ
Who Amplifies Andy Hahn
Physicians who reposted Andy Hahn’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| GU Cancer | #18 | — | 30 | 30 | Full ranking |
What Colleagues Are Saying About Andy Hahn
2026 posts by fellow physicians that mention @OncHahn, quoted word for word.
Stay tuned for the presentation of JNJ-6143, a riptac molecule, in patients with mCRPC. Barcelona Auditorium. Hall 9 at #ESMO2026. @SarahCannonDocs @SCRIOncology. Particular thanks to @OncHahn for his help and support of my presentation. Come see a new MOA! #ProstateCancer
Trials Andy Hahn Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| JNJ-6143 | 1 | #1 of 16 | Oct 24, 2026 |
Andy Hahn on JNJ-6143
Thrilled to share updated results from JNJ-6143, the AR-BRD4 RIPTAC therapy, presented by @BGarmezy. Totally novel MOA was well tolerated, oral pill and produced significant benefit for pts (PSA90 50%, ORR 68%). P2 trial active now and more coming. Lots of potential! https://t.co/spwrXBg5ZZ
Andy Hahn’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Great points @AmandaNizamMD Lenvatinib seems to provide much of the benefit. Belzutifan alone produces durable responses in a minority. Unclear to me why we should give up tolerability of belzutifan and mTORi as a MOA for ccRCC https://t.co/xVEl9tchsD
Industry Payments
CMS Open Payments · 2025 general payments
$21,875 across 37 payments